Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2906191 | PMC |
| http://dx.doi.org/10.2450/2009.0101-09 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Obinutuzumab-induced severe acute thrombocytopenia: a case report and literature review.
Front Immunol
September 2025
Department of Haematology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.
Obinutuzumab is a humanized type II anti-CD20 monoclonal antibody that is widely used in B-cell lymphomas including follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Multiple clinical studies have shown that compared with rituximab combined with chemotherapy, obinutuzumab combined with chemotherapy can significantly improve the progression-free survival (PFS) of patients, effectively reduce the risk of disease progression, and improve patient prognosis. The main adverse effects of obinutuzumab include infusion reactions, myelosuppression, infection, cardiotoxicity, tumor lysis syndrome (TLS), etc.
View Article and Find Full Text PDFAutoimmune Hemolytic Anemia From Tofacitinib Use in a Patient With Ulcerative Colitis.
ACG Case Rep J
October 2024
Department of Medicine, Division of Gastroenterology and Hepatology, University of Maryland Medical System, Baltimore, MD.
Tofacitinib is a Janus kinase inhibitor commonly used in the management of rheumatoid arthritis and moderate-to-severe ulcerative colitis. Anemia is a rare side effect of this medication often with minimal changes in hemoglobin levels. We report the first case of autoimmune hemolytic anemia from tofacitinib use in a patient with inflammatory bowel disease.
View Article and Find Full Text PDFAutoimmune nodopathies: emerging insights and clinical implications.
Curr Opin Neurol
October 2025
Neuromuscular Diseases Unit, Department of Neurology, IR SANT PAU, Hospital de la Santa Creu i Sant Pau, CIBERER, Barcelona, Spain.
Purpose Of Review: Autoimmune nodopathies (AN) are a recognized distinct group of immune-mediated peripheral neuropathies with unique immunopathological features and therapeutic implications. This review synthesizes recent advances in their pathogenesis, diagnosis, and management, which have refined their clinical classification and informed targeted treatment strategies.
Recent Findings: AN are characterized by autoantibodies targeting surface proteins in the nodal-paranodal area (anti-contactin-1, anti-contactin-associated protein 1, anti-neurofascin-155, anti-pan-neurofascin), predominantly of IgG4 subclass.
Management of rituximab in patients with PLA2R-associated membranous nephropathy of different age: a single-center retrospective cohort study.
Ren Fail
December 2025
Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Background: Rituximab (RTX) has become the first-line therapy for idiopathic membranous nephropathy (IMN). The safety of low-dose and long-course RTX regimen in elderly patients with IMN remains unknown.
Methods: Sixty-nine IMN patients with anti-M-phospholipase A2 receptor (PLA2R) antibodies-positive were recruited for this study.
Role for long term treatment in NMOSD induced by the immune checkpoint inhibitor cemiplimab.
Clin Neurol Neurosurg
October 2025
Department of Neurology, University Hospitals Leuven, Leuven, Belgium.
We present the case of a 54-year-old patient treated with cemiplimab, an immune checkpoint inhibitor (ICI), for multiple basal cell carcinomas in the context of Gorlin Goltz syndrome. Gorlin Goltz syndrome is an autosomal dominant multisystem disorder characterized, among other features, by multiple early-onset basal cell carcinomas (BCCs). After receiving Cemiplimab, she developed aquaporin-4 antibody (AQP4-Ab) positive neuromyelitis optica spectrum disorder (NMOSD).
View Article and Find Full Text PDF